From a CRISPR therapy's FDA priority review to oral HAE prophylaxis data and a needle-free epinephrine resubmission, 4 allergy stories from September.
News|Articles|April 7, 2026
Q1 2026 Recap: Allergy News and Updates
Author(s)Chelsie Derman
Fact checked by: Tim Smith
FDA approvals, new HAE guidance, epinephrine access shifts, and phase 3 peanut patch data defined major allergy developments across Q1 2026.
Advertisement
Advertisement
The first quarter of 2026 delivered a series of regulatory milestones, guideline updates, and late-phase clinical data that reshaped key areas across
Related to this article
DBV has requested priority review for the epicutaneous patch, supported by phase 3 VITESSE data showing a 31.8-point responder rate gain vs placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Ryaltris pediatric approval, lonvo-z and deucrictibant HAE filings, PVX108 Fast Track, and Palforzia's exit headline Q3 2026 allergy news.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
Advertisement
Advertisement